Sanofi wades into AATD in $1.7B bid for Inhibrx's rare disease drug

Max Gelman

Senior Editor

In its first M&A move of 2024, Sanofi is grabbing what it sees as a potential best-in-class therapy for its rare disease pipeline by snapping up Inhibrx in a $1.7 billion deal.

While Sanofi is nominally acquiring the whole of Inhibrx, it will only keep the lead drug — a Phase II human recombinant protein designed to treat alpha-1 antitrypsin deficiency, or AATD — while all the other programs get spun out into a separate company called New Inhibrx. The French drugmaker will also retain an 8% equity stake in New Inhibrx.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Sanofi wades into AATD in $1.7B bid for Inhibrx's rare disease drug

Amber Tong

Senior Editor

Max Gelman

Senior Editor

Unlock this article instantly by becoming a free subscriber.

House to mark up bill targeting Chinese biotech and genomics companies

Amgen touts new data for obesity drug MariTide, moving rapidly into Phase 3 work

AbbVie puts $161M into new R&D site in Germany, will add 300 jobs

CG Oncology touts interim Phase 3 bladder cancer data, gears up to compete with ImmunityBio

BridgeBio spins out oncology unit with $200M in backing for RAS assets

A New Precision Approach for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Sanofi wades in­to AATD in $1.7B bid for In­hi­brx's rare dis­ease drug

Senior Editor

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Sanofi wades into AATD in $1.7B bid for Inhibrx's rare disease drug